Recombinant leukocyte A interferon: An active agent in advanced cutaneous T-cell lymphomas Academic Article uri icon


MeSH Major

  • Interferon Type I
  • Lymphoma
  • Skin Neoplasms


  • High-dose recombinant leukocyte A interferon (50 X 10(6) U/m2 body surface area, intramuscularly, three times weekly) was tested in a clinical trial involving patients with advanced cutaneous T-cell lymphomas to determine its effectiveness and toxicity. All 20 patients had advanced stages of disease refractory to two or more standard therapies. Objective partial remissions lasting 3 months to more than 25 months (median, 5 months) were documented in 9 patients. The major dose-limiting toxicity was a severe influenza-like syndrome with malaise, anorexia, depression, weight loss, and decreased performance status; this effect was reversible after dose reductions in all patients and did not recur with re-escalation of doses in 10 patients. This interferon preparation is highly effective in the treatment of advanced refractory cutaneous T-cell lymphomas, and new schedules to reduce toxicity and achieve complete responses, combined treatment with chemotherapy or serotherapy, and its use in earlier stages of disease should be investigated.

publication date

  • December 13, 1984



  • Academic Article



  • eng

PubMed ID

  • 6332565

Additional Document Info

start page

  • 484

end page

  • 7


  • 101


  • 4